Posted by Michael Wonder on 12 May 2022
FDA grants breakthrough device designation to Remedee Labs for its groundbreaking endorphin stimulation solution for the management of fibromyalgia
12 May 2022 - On World Fibromyalgia Awareness Day (May 12), the French startup Remedee Labs is announcing that the FDA has granted Breakthrough Device Designation to its endorphin stimulator for fibromyalgia patients.
The endorphin stimulation technology developed by Remedee Labs is a new non-pharmaceutical approach to pain treatment for fibromyalgia patients, offering relief from major symptoms including pain, sleep disorders, fatigue, and stiffness.
